UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Information Required in Proxy Statement Schedule 14A Information

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ⊠		
Filed by a Party other than the Registrant		
Check the appropriate box:		
	Preliminary Proxy Statement	
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
	Definitive Proxy Statement	
\boxtimes	Definitive Additional Materials	
	Soliciting Material under §240.14a-12	
	KYMERA THERAPEUTICS, INC. (Name of Registrant as Specified in its Charter)	
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Payment of Filing Fee (Check all boxes that apply):		
\boxtimes	No fee required	
	Fee paid previously with preliminary materials	
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11	



KYMERA THERAPEUTICS, INC.

2024 Annual Meeting Vote by June 17, 2024 11:59 PM ET



V42985-P08465

You invested in KYMERA THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 18, 2024.

Get informed before you vote

KYMERA

KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, FOURTH FLOOR WATERTOWN, MA 02472

View the Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by request prior to June 4, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number



Vote Virtually at the Meeting*

June 18, 2024 8:30 AM, ET

Virtually at: www.virtualshareholdermeeting.com/KYMR2024

^{*}Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	
To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;	
Nominees:	⊘ For
01) Pamela Esposito, Ph.D. 02) Gorjan Hrustanovic, Ph.D. 03) Victor Sandor, M.D.C.M.	0 101
To approve, on a non-binding advisory basis, the compensation of our named executive officers;	O For
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and	⊘ For
To approve an amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan.	⊘ For
NOTE: To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. You may attend the Annual Meeting via the internet at www.virtualshareholdermeeting.com/KYMR2024 and vote during the meeting. Have your 16-digit control number available and follow the instructions.	
	To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal; Nominees: 01) Pamela Esposito, Ph.D. 02) Gorjan Hrustanovic, Ph.D. 03) Victor Sandor, M.D.C.M. To approve, on a non-binding advisory basis, the compensation of our named executive officers; To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and To approve an amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan. TE: To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the unal Meeting. You may attend the Annual Meeting via the internet at www.virtualshareholdermeeting.com/KYMR2024

V42986-P08465

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".